Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure

Leukemia Research

Volumn 39, Issue 5, 2015, Pages 501-504

  Harel, Stéphanie ^a   Cherait, Amina ^a   Berthon, Céline ^b   Willekens, Christophe ^b   Park, Sophie ^c   Rigal, Marthe ^a   Brechignac, Sabine ^a   Thépot, Sylvain ^a   Quesnel, Bruno ^b   Gardin, Claude ^a   Adès, Lionel ^a,d   Fenaux, Pierre ^a,d   Braun, Thorsten ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Azacitidine failure; CMML; Decitabine; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLOFARABINE; RIGOSERTIB; ANTINEOPLASTIC ANTIMETABOLITE; DECITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MALIGNANT TRANSFORMATION; MEDICAL RECORD REVIEW; MONOSOMY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; SKIN DEFECT; SPLENOMEGALY; TREATMENT DURATION; TRISOMY; VERY ELDERLY; ANALOGS AND DERIVATIVES; DISEASE COURSE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84928074222     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.02.004     Document Type: Article

References (16)

1. Adès L., Itzykson R., Fenaux P. Myelodysplastic syndromes. Lancet 2014, 10.1016/S0140-6736(13)61901-7.
2. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20(10):2429-2440.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232. 10.1016/S1470-2045(09)70003-8.
4. Prebet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29(24):3322-3327. 10.1200/JCO.2011.35.8135.
5. Bravo G.M., Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia 2014, 10.1038/leu.2014.244.
6. Kantarjian H.M., Thomas X.G., Dmoszynska A., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30(21):2670-2677. 10.1200/JCO.2011.38.9429.
7. Hollenbach P.W., Nguyen A.N., Brady H., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5(2):e9001. 10.1371/journal.pone.0009001.
8. Venturelli S., Berger A., Weiland T., et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. Mol Cancer Ther 2013, 12(10):2226-2236. 10.1158/1535-7163.MCT-13-0137.
9. Borthakur G., El Ahdab S., Ravandi F., et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008, 49(4):690-695. 10.1080/10428190701882146.
10. Bhatnagar B., Zandberg D., Vannorsdall E., et al. Lack of Response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to Decitabine After Failure of Azacitidine. ASH Annual Meeting Abstract 2012.
11. Duong V.H., Bhatnagar B., Zandberg D.P., et al. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leuk Lymphoma 2014, 1-5. 10.3109/10428194.2014.966708.
12. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109(1):52-57. 10.1182/blood-2006-05-021162.
13. Steensma D.P., Baer M.R., Slack J.L., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27(23):3842-3848. 10.1200/JCO.2008.19.6550.
14. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425. 10.1182/blood-2005-10-4149.
15. Wattel E., Guerci A., Hecquet B., et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. Blood 1996, 88(7):2480-2487.
16. Prebet T., Braun T., Beyne-Rauzy O., et al. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leuk Res 2014, 38(1):29-33. 10.1016/j.leukres.2013.07.023.